Search results for "Mesalazine"

showing 3 items of 13 documents

Mesalazine for the treatment of inflammatory bowel disease

2013

Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission. Mesalazine therapies are available both as oral delayed-release and sustained-release formulation, topical formulations and as prodrug.Available literature regarding mesalazine is extensively reviewed in this article, covering its mechanism of action, pharmaceutics and pharmacokinetics, clinical efficacy, safety and tolerability in different settings.Mesalazine has a well-established role in the management of UC. It is the treatment of choice in active and inactive mild-to-moderate UC combinin…

medicine.medical_specialtyColorectal cancerDiseaseGastroenterologyInflammatory bowel diseasechemistry.chemical_compoundCrohn DiseaseMesalazineInternal medicineSecondary PreventionmedicineHumansPharmacology (medical)Intestinal MucosaColitisMesalaminePharmacologyCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicinemedicine.diseaseUlcerative colitischemistryTolerabilityColitis UlcerativeColorectal NeoplasmsbusinessExpert Opinion on Pharmacotherapy
researchProduct

An update on medical management on Crohn's disease.

2014

The management of Crohn's disease (CD) is continuously evolving. New issues emerging from more recent studies could influence the decision-making process in clinical practice.The aim of this review article is to highlight critical issues on the management of CD, new evidence from clinical trials, long-term prospective studies and real life experience, beyond the current guidelines.The role of mucosal healing in clinical practice is uncertain, clinical remission remains the primary end point. The timing for the definition of steroid-resistant CD should be considered between 2 and 4 weeks. Early treatment strategy with immunomodulators is effective for inducing remission but no controlled dat…

medicine.medical_specialtyCombination therapyAzathioprineDiseasechemistry.chemical_compoundMesalazineAdjuvants ImmunologicCrohn DiseaseClinical endpointMedicineHumansPharmacology (medical)Prospective StudiesIntensive care medicinePharmacologyCrohn's diseaseBiological ProductsClinical Trials as Topicbusiness.industryTumor Necrosis Factor-alphaRemission InductionGeneral Medicinemedicine.diseaseReview articleSurgeryClinical trialchemistryPractice Guidelines as TopicDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drugExpert opinion on pharmacotherapy
researchProduct

BENEFICIAL EFFECT OF PROBIOTICS ADMINISTRATION IN INFLAMMATORY BOWEL DISEASE AND RELATED SPONDYLOARTHROPATHY: A PROSPECTIVE STUDY

2015

Background: Therapeutic treatment for inflammatory bowel disease (IBD) may follow different approaches, systemic as well as local, especially when the target is the osteoarticular apparatus. Although some clinical trials have suggested benefits from probiotics administration in IBD, there is still a great deal of controversy on their use. The aim of this study was to further investigate the effects of probiotics in patients with IBD and related spondyloarthropathy. Material/Methods: Fifty-nine patients affected by IBD with extra-intestinal involvement where evaluated from 2006 to 2010. Twenty-eight patients received administration of a standard therapy with mesalazine and 31 where treated w…

medicine.medical_specialtySettore MED/09 - Medicina InternaSpondyloarthropathyBiomedical EngineeringBioengineeringInflammatory bowel diseaseGastroenterologylaw.inventionchemistry.chemical_compoundProbioticMesalazineRandomized controlled triallawInternal medicinemedicineIn patientProspective cohort studyGeneral PsychologyInflammatory Bowel Disease IBD Microbiome Dysbiosis MALTbusiness.industrySettore BIO/16 - Anatomia UmanaGeneral Medicinemedicine.diseaseClinical trialSettore MED/18 - Chirurgia Generalechemistrybusiness
researchProduct